journal
Journals Current Treatment Options in O...

Current Treatment Options in Oncology

https://read.qxmd.com/read/38478330/update-on-dosing-and-fractionation-for-neoadjuvant-radiotherapy-for-localized-soft-tissue-sarcoma
#1
REVIEW
Siyer Roohani, Lisette M Wiltink, David Kaul, Mateusz Jacek SpaƂek, Rick L Haas
Neoadjuvant radiotherapy (RT) over 5-6 weeks with daily doses of 1.8-2.0 Gy to a total dose of 50-50.4 Gy is standard of care for localized high-grade soft tissue sarcomas (STS) of the extremities and trunk wall. One exception is myxoid liposarcomas where the phase II DOREMY trial applying a preoperative dose of 36 Gy in 2 Gy fractions (3-4 weeks treatment) has achieved excellent local control rates of 100% after a median follow-up of 25 months.Hypofractionated preoperative RT has been investigated in a number of phase II single-arm studies suggesting that daily doses of 2...
March 13, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38478329/ovarian-suppression-early-menopause-and-late-effects
#2
REVIEW
Chiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, Roberto Borea, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Cynthia Villarreal-Garza, Jyoti Bajpai, Hee Jeong Kim, Silvia Puglisi, Evandro de Azambuja, Matteo Lambertini
Around 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine therapy, tailored according to disease stage, biological characteristics of the tumour, patient's comorbidities, preferences and age. In premenopausal patients with hormone receptor-positive breast cancer, ovarian function suppression is a key component of the adjuvant endocrine treatment in combination with an aromatase inhibitor or tamoxifen...
March 13, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38472567/circulating-tumor-dna-ctdna-and-its-role-in-gynecologic-malignancies
#3
REVIEW
Tali Pomerantz, Rebecca Brooks
Circulating tumor DNA (ctDNA) refers to small fragments of DNA released into the bloodstream by cancer cells. It is obtained through "liquid biopsy;" which most commonly refers to plasma or blood samples, but can be obtained from a number of bodily fluids including ascitic fluid, saliva, and even urine and stool. ctDNA is detected via polymerase chain reaction (PCR) or next-generation sequencing (NGS). The DNA from these samples is analyzed for the detection of point mutations, copy-number alterations, gene fusion, and DNA methylation...
March 12, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38386240/neoadjuvant-short-vs-long-course-radiation-for-locally-advanced-rectal-cancer-how-to-choose
#4
REVIEW
Christopher G Willett, Scarlett Acklin-Wehnert
Over the past decades, the treatment of locally advanced rectal cancer has evolved dramatically due to improvements in diagnostic imaging, surgical technique, and the addition of radiotherapy and/or chemotherapy. Fractionation of neoadjuvant radiotherapy with or without concurrent chemotherapy remains the subject of discussion and the question multiple recent trials have aimed to answer. In light of recent data and concern for locoregional recurrence, our institution favors long-course chemoradiation in most cases, especially in low-lying primaries, threatened circumferential resection margin, consideration of non-operative management, or if the surgeon has concerns for resectability...
February 22, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38372853/a-comprehensive-review-of-cancer-drug-induced-cardiotoxicity-in-blood-cancer-patients-current-perspectives-and-therapeutic-strategies
#5
REVIEW
Vincenzo Costanzo, Yashwant Kumar Ratre, Emanuela Andretta, Rakesh Acharya, L V K S Bhaskar, Henu Kumar Verma
Cardiotoxicity has emerged as a serious outcome catalyzed by various therapeutic targets in the field of cancer treatment, which includes chemotherapy, radiation, and targeted therapies. The growing significance of cancer drug-induced cardiotoxicity (CDIC) and radiation-induced cardiotoxicity (CRIC) necessitates immediate attention. This article intricately unveils how cancer treatments cause cardiotoxicity, which is exacerbated by patient-specific risks. In particular, drugs like anthracyclines, alkylating agents, and tyrosine kinase inhibitors pose a risk, along with factors such as hypertension and diabetes...
February 19, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38372852/who-should-receive-immunotherapy-for-advanced-gastroesophageal-cancer
#6
REVIEW
Suhaib Khateeb, Ludimila Cavalcante, Noor Alnairat, Meghana Singh, Ibrahim Halil Sahin, Azhar Saeed, Anwaar Saeed
This paper shines a light on the exciting progress being made in using immunotherapy to treat advanced gastroesophageal cancers. The positive results from trials using drugs like Pembrolizumab and Nivolumab are certainly encouraging and open new possibilities for treating this challenging disease. However, it is clear that we still have a lot to learn about how to predict which patients will benefit most from these treatments. The exploration of combining therapies and using machine learning to guide treatment shows promise...
February 19, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38367182/harnessing-the-potential-of-real-world-evidence-in-the-treatment-of-colorectal-cancer-where-do-we-stand
#7
REVIEW
Sietske C M W van Nassau, Guus M Bol, Frederieke H van der Baan, Jeanine M L Roodhart, Geraldine R Vink, Cornelis J A Punt, Anne M May, Miriam Koopman, Jeroen W G Derksen
Treatment guidelines for colorectal cancer (CRC) are primarily based on the results of randomized clinical trials (RCTs), the gold standard methodology to evaluate safety and efficacy of oncological treatments. However, generalizability of trial results is often limited due to stringent eligibility criteria, underrepresentation of specific populations, and more heterogeneity in clinical practice. This may result in an efficacy-effectiveness gap and uncertainty regarding meaningful benefit versus treatment harm...
February 17, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38353859/antiepileptic-strategies-for-patients-with-primary-and-metastatic-brain-tumors
#8
REVIEW
Herbert B Newton, Jenna Wojkowski
Seizure activity is common in patients with primary and metastatic brain tumors, affecting more than 50% of cases over the course of their disease. Several mechanisms contribute to brain tumor-related epilepsy (BTRE), including a pro-inflammatory environment, excessive secretion of glutamate and an increase in neuronal excitatory tone, reduction of GABAergic inhibitory activity, and an increase in 2-hydroxygluturate production in isocitrate dehydrogenase mutant tumors. After a verified seizure in a brain tumor patient, the consensus is that BTRE has developed, and it is necessary to initiate an antiepileptic drug (AED)...
February 14, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38349502/preoperative-strategies-for-locally-advanced-colon-cancer
#9
REVIEW
Kanika G Nair, Suneel D Kamath, Nivan Chowattukunnel, Smitha S Krishnamurthi
Neoadjuvant chemotherapy is safe for patients with locally advanced colon cancer (LACC). The FOxTROT trial demonstrated a reduction in residual and recurrent cancer at 2 years with neoadjuvant chemotherapy for patients with cT3-4 LACC. Preoperative chemotherapy should be avoided, if possible, for patients with dMMR LACC, as over 50% of dMMR cancers have no pathologic response. Early universal testing of MMR status is critical to selecting the appropriate neoadjuvant therapy. Concerns about CT staging of LACC have limited uptake of neoadjuvant chemotherapy, as approximately 25% of patients with cT3-T4 cancer on CT have low-risk stage II disease...
February 13, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38324075/a-comprehensive-review-on-the-role-of-lurbinectedin-in-soft-tissue-sarcomas
#10
REVIEW
Rita Khoury, Tarek Assi, Rebecca Ibrahim, Tony Ibrahim, Benjamin Verret, Clemence Henon, Ratislav Bahleda, Axel Le Cesne
Soft tissue sarcoma (STS), a substantial group of aggressive and rare tumors with tissue heterogeneity, is infrequently represented in clinical trials with an urgent necessity for newer treatment options. Lurbinectedin, an analog of trabectedin, is currently approved, in various countries, as a single agent, for the treatment of patients with relapsed small cell lung cancer (SCLC). However, preclinical and phase I and phase II trials have demonstrated the efficacy of lurbinectedin in different tumor types, including STS...
February 7, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38315403/one-size-fits-some-approaching-rare-malignancies-of-the-urinary-tract
#11
REVIEW
Stephanie A Berg, Bradley A McGregor
Urothelial carcinoma is the predominant cancer of the urinary tract but when divergent and subtype histology (non-urothelial) are identified at time of pathologic diagnosis, therapeutic and diagnostic challenges transpire. To this end, pathologic review to confirm any non-urothelial histology is key since these subtypes can often be overlooked. Few prospective trials are dedicated to understanding these non-urothelial histologic types; however, current, and past trials did allow patients with these non-urothelial histologic types to enroll, and inferences can be made about treatment efficacy and survival...
February 5, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38300480/integrating-systemic-therapies-into-the-multimodality-therapy-of-patients-with-craniopharyngioma
#12
REVIEW
David Gritsch, Sandro Santagata, Priscilla K Brastianos
The integration of targeted therapy into the multimodal management of craniopharyngiomas represents a significant advancement in the field of neuro-oncology. Historically, the management of these tumors has been challenging due to their proximity to vital brain structures, necessitating a delicate balance between tumor control and the preservation of neurological function. Traditional treatment modalities, such as surgical resection and radiation, while effective, carry their own set of risks, including potential damage to surrounding healthy tissues and the potential for long-term side effects...
February 1, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38300479/evaluation-of-homologous-recombination-deficiency-in-ovarian-cancer
#13
REVIEW
Rubina Ratnaparkhi, Melissa Javellana, Andrea Jewell, Lori Spoozak
Homologous recombination deficiency (HRD) is an important biomarker guiding selection of ovarian cancer patients who will derive the most benefit from poly(ADP-ribose) polymerase inhibitors (PARPi). HRD prevents cells from repairing double-stranded DNA damage with high fidelity, PARPis limit single-stranded repair, and together these deficits induce synthetic lethality. Germline or somatic BRCA mutations represent the narrowest definition of HRD, but do not reflect all patients who will have a durable PARPi response...
February 1, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38286894/research-progress-on-the-use-of-metformin-in-leukemia-treatment
#14
REVIEW
Qian Wang, Xudong Wei
Metformin is a first-line drug in the clinical treatment of type 2 diabetes. Its main molecular mechanism involves the activation of adenosine 5'-monophosphate-activated protein kinase (AMPK), which regulates cell energy metabolism. Many clinical studies have shown that metformin can reduce the incidence and mortality of cancer in patients with or without diabetes. In vitro studies also confirmed that metformin can inhibit proliferation, promote apoptosis, and enhance the response of cells to chemical drugs and other anticancer effects on a variety of leukemia cells...
January 30, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38270802/impact-of-psma-pet-on-prostate-cancer-management
#15
REVIEW
Adam B Weiner, Raag Agrawal, Luca F Valle, Ida Sonni, Amar U Kishan, Matthew B Rettig, Steven S Raman, Jeremie Calais, Paul C Boutros, Robert E Reiter
PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility...
January 25, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38270798/desmoid-tumors-current-perspective-and-treatment
#16
REVIEW
Ankit Mangla, Nikki Agarwal, Gary Schwartz
Desmoid tumors are rare tumors with a tendency to infiltrate locally. The lack of a standard treatment approach makes choosing the most appropriate treatment for patients challenging. Most experts recommend watchful observation for asymptomatic patients as spontaneous regression of tumor is observed in up to 20% of patients. Upfront resection of the desmoid tumor has fallen out of favor due to high morbidity and high relapse rates associated with the tumor. Systemic therapy has evolved over several decades...
January 25, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38177560/current-standards-multidisciplinary-approaches-and-future-directions-in-the-management-of-extrahepatic-cholangiocarcinoma
#17
REVIEW
Margaret Wheless, Rajiv Agarwal, Laura Goff, Natalie Lockney, Chandrasekhar Padmanabhan, Thatcher Heumann
Biliary tract cancers are molecularly and anatomically diverse cancers which include intrahepatic cholangiocarcinoma, extrahepatic (perihilar and distal) cholangiocarcinoma, and gallbladder cancer. While recognized as distinct entities, the rarer incidence of these cancers combined with diagnostic challenges in classifying anatomic origin has resulted in clinical trials and guideline recommended strategies being generalized patients with all types of biliary tract cancer. In this review, we delve into the unique aspects, subtype-specific clinical trial outcomes, and multidisciplinary management of patients with extrahepatic cholangiocarcinoma...
January 5, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38311708/targeting-brca-and-palb2-in-pancreatic-cancer
#18
REVIEW
Sriram Anbil, Kim A Reiss
An important subgroup of pancreatic ductal adenocarcinomas (PDACs) harbor pathogenic variants in BRCA1, BRCA2, or PALB2. These tumors are exquisitely sensitive to platinum-based chemotherapy and patients may experience deep and durable responses to this treatment. PARP inhibitors offer potential respite from the cumulative toxicities of chemotherapy as they significantly extend progression-free survival compared to a chemotherapy holiday. Given the lack of proven survival benefit, the decision to use a maintenance PARP inhibitor rather than continue chemotherapy should be individualized...
January 4, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38291265/metastatic-hormone-sensitive-prostate-cancer-in-the-era-of-doublet-and-triplet-therapy
#19
REVIEW
Anthony V Serritella, Maha Hussain
Treatment for metastatic hormone-sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now which is almost 6 years. The timing and extent of metastatic disease combined with individual patient factors helps treatment recommendation of doublet therapy including androgen deprivation (ADT) plus either chemotherapy or androgen receptor signaling inhibition (ARSI) or triplet therapy with ADT+ARSI+chemotherapy...
January 4, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38270801/intraperitoneal-and-hyperthermic-intraperitoneal-chemotherapy-for-the-treatment-of-ovarian-cancer
#20
REVIEW
Joyce Y Wang, Maya Gross, Renata R Urban, Soledad Jorge
In our clinical practice, we have shifted away from the use of adjuvant normothermic intraperitoneal (IP) chemotherapy, particularly following the publication of GOG 252. Our decision is rooted in the accumulating evidence indicating a lack of demonstrable superiority, alongside the recognized toxicities and logistical challenges associated with its administration. This strategic departure is also influenced by the rising utilization of maintenance therapies such as bevacizumab and PARP inhibitors, which present viable alternatives for improving patient outcomes...
January 4, 2024: Current Treatment Options in Oncology
journal
journal
34852
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.